4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006[J]. CA Cancer J Clin, 2006, 56(2): 106-130.
5Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal eytoreduetive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis[ J ]. J Clin Oncol, 2002, 20 (5) : 1248 - 1259.
6Lee SJ, Kim BG, Lee JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery[ J]. J Obstet Gynaecol Res, 2006, 32 ( 1 ) : 99 - 106.
7Pectasides D, Farmakis D, Koumarianou A. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer [ J ]. Oncology, 2005, 68 ( 1 ) : 64 - 70.
8Steed H, Oza AM, Murphy J, et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer [ J]. Int J Gynecol Cancer, 2006, 16 (Suppl1):47-53.
9Le T, Alshaikh G, Hopkins L, et al. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking[ J ]. Ann Surg Oncol, 2006, 13 ( 12 ) : 1711 - 1716.
10Le T, Faught W, Hopkins L, et al. Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer[ J]. Int J Gynecol Cancer, 2005, 15(5) : 770 - 775.
